cel-sci corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. the company's lead investigational immunotherapy is multikine, which is under phase iii clinical trial for the treatment of head and neck cancer. its ligand epitope antigen presentation system (leaps), a pre-clinical patented t-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. the company also develops leaps-h1n1-dc; cel-2000 and cel-4000 are product candidates for the treatment of rheumatoid arthritis; and leaps cov-19, a product candidate to treat covid-19 coronavirus. cel-sci corporation has a collaboration agreement with the university of georgia's center for vaccines and immunology to develop leaps covid-19 immunotherapy. the company was founded in 1983 and is headquartered in vienna, virginia.
Company profile
Ticker
CVM
Exchange
Website
CEO
Geert Kersten
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
INTERLEUKIN 2 INC
SEC CIK
Corporate docs
IRS number
840916344
CVM stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
23 Apr 24
8-K
Submission of Matters to a Vote of Security Holders
19 Apr 24
DEFA14A
Additional proxy soliciting materials
7 Mar 24
ARS
2023 FY
Annual report to shareholders
7 Mar 24
DEF 14A
Definitive proxy
7 Mar 24
10-Q
2024 Q1
Quarterly report
14 Feb 24
8-K
Entry into a Material Definitive Agreement
13 Feb 24
424B5
Prospectus supplement for primary offering
9 Feb 24
S-8
Registration of securities for employees
22 Dec 23
10-K
2023 FY
Annual report
21 Dec 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Sep 23 | Sep 22 | Sep 21 | Sep 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 4.15 mm | 4.15 mm | 4.15 mm | 4.15 mm | 4.15 mm | 4.15 mm |
Cash burn (monthly) | 329.78 k | 1.54 mm | 2.49 mm | 2.62 mm | 1.68 mm | 1.90 mm |
Cash used (since last report) | 2.26 mm | 10.60 mm | 17.09 mm | 18.01 mm | 11.55 mm | 13.07 mm |
Cash remaining | 1.88 mm | -6.45 mm | -12.95 mm | -13.86 mm | -7.40 mm | -8.93 mm |
Runway (months of cash) | 5.7 | -4.2 | -5.2 | -5.3 | -4.4 | -4.7 |
Institutional ownership, Q3 2023
9.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 66 |
Opened positions | 8 |
Closed positions | 3 |
Increased positions | 15 |
Reduced positions | 13 |
13F shares | Current |
---|---|
Total value | 6.50 bn |
Total shares | 5.33 mm |
Total puts | 97.30 k |
Total calls | 351.40 k |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 1.90 mm | $2.38 bn |
BLK Blackrock | 755.97 k | $944.96 mm |
Advisor | 737.88 k | $922.35 mm |
Geode Capital Management | 457.80 k | $572.41 mm |
STT State Street | 154.41 k | $193.01 mm |
Bridgeway Capital Management | 149.90 k | $187.38 mm |
Cutter & CO Brokerage | 102.85 k | $128.56 mm |
Thoroughbred Financial Services | 101.76 k | $127.00 k |
Sonic GP | 100.00 k | $125.00 mm |
NTRS Northern Trust | 78.24 k | $97.79 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
19 Apr 24 | Watson Robert Eugene | Options Common Stock | Grant | Acquire A | No | No | 0.01 | 64,000 | 640.00 | 698,000 |
19 Apr 24 | Baillavoine Bruno Jean-marie | Options Common Stock | Grant | Acquire A | No | No | 0.01 | 64,000 | 640.00 | 725,500 |
19 Apr 24 | Talor Eyal | Options Common Stock | Grant | Acquire A | No | No | 0.01 | 182,000 | 1.82 k | 1,998,646 |
19 Apr 24 | Prichep Patricia B | Options Common Stock | Grant | Acquire A | No | No | 0.01 | 167,000 | 1.67 k | 1,893,797 |